Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -0.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.28 | N/A | -0.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing their commitment to ongoing projects. They did not provide specific future guidance.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite the financial results.
Sarepta Therapeutics reported a loss per share of $-0.28, which was below expectations, although no revenue figures were disclosed. The stock reacted negatively, declining by 0.31%. The lack of guidance and focus on pipeline advancement suggests uncertainty in the near term, which may have influenced investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MPLX LP
Apr 30, 2018